Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 1634 |
| PDBID: | 5O7P |
| Chains: | BA_C |
| Organism: | Homo sapiens |
| Method: | XRD |
| Resolution (Å): | 4.50 |
| Reference: | 10.1016/j.ccell.2018.04.003 |
| Antibody | |
| Antibody: | MF3178 Fab |
| Antibody mutation: | No |
| INN (Clinical Trial): | Zenocutuzumab(Phase-II) |
| Antigen | |
| Antigen: | Receptor tyrosine-protein kinase erbB-3 |
| Antigen mutation: | No |
| Durg Target: | P21860 |
Sequence information
Antibody
Heavy Chain: B
Mutation: NULL
| >5O7P_B|Chain C[auth B]|MF3178 FAB heavy chain|Homo sapiens (9606) MGWSCIILFLVLLLAQPAMAQVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDHGSRHFWSYWGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCAAA |
Light Chain: A
Mutation: NULL
| >5O7P_A|Chain B[auth A]|MF3178 FAB light chain|Homo sapiens (9606) DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Antigen
Chain: C
Mutation: NULL
| >5O7P_C|Chain A[auth C]|Receptor tyrosine-protein kinase erbB-3|Homo sapiens (9606) MRANDALQVLGLLFSLARGSEVGNSQAVCPGTLNGLSVTGDAENQYQTLYKLYERCEVVMGNLEIVLTGHNADLSFLQWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDGKFAIFVMLNYNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGRSCPPCHEVCKGRCWGPGSEDCQTLTKTICAPQCNGHCFGPNPNQCCHDECAGGCSGPQDTDCFACRHFNDSGACVPRCPQPLVYNKLTFQLEPNPHTKYQYGGVCVASCPHNFVVDQTSCVRACPPDKMEVDKNGLKMCEPCGGLCPKACEGTGSGSRFQTVDSSNIDGFVNCTKILGNLDFLITGLNGDPWHKIPALDPEKLNVFRTVREITGYLNIQSWPPHMHNFSVFSNLTTIGGRSLYNRGFSLLIMKNLNVTSLGFRSLKEISAGRIYISANRQLCYHHSLNWTKVLRGPTEERLDIKHNRPRRDCVAEGKVCDPLCSSGGCWGPGPGQCLSCRNYSRGGVCVTHCNFLNGEPREFAHEAECFSCHPECQPMEGTATCNGSGSDTCAQCAHFRDGPHCVSSCPHGVLGAKGPIYKYPDVQNECRPCHENCTQGCKGPELQDCLGQTLVLIGKTHLTHHHHHH |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| A: GLN27 SER30 TYR32 SER91 TYR92 SER93 THR94 PRO95 B: ARG103 PHE105 TRP106 SER107 TRP109 C: GLN400 TYR424 ASN425 ARG426 GLY427 PHE428 LEU431 MET433 LYS434 ARG453 TYR455 GLU480 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
